Anti-cytokine therapies in T1D: Concepts and strategies
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Immunology |
Vol/bind | 149 |
Udgave nummer | 3 Part A |
Sider (fra-til) | 279-85 |
Antal sider | 7 |
ISSN | 1521-6616 |
DOI | |
Status | Udgivet - dec. 2013 |
ID: 113810511